JP2018506964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506964A5 JP2018506964A5 JP2017535814A JP2017535814A JP2018506964A5 JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5 JP 2017535814 A JP2017535814 A JP 2017535814A JP 2017535814 A JP2017535814 A JP 2017535814A JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- cell
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004671 cell-free system Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 102000004195 Isomerases Human genes 0.000 claims description 4
- 108090000769 Isomerases Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 3
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- -1 E or D Chemical class 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 102000044459 human CD47 Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 101150036449 SIRPA gene Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098291P | 2014-12-30 | 2014-12-30 | |
| US62/098,291 | 2014-12-30 | ||
| PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Division JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506964A JP2018506964A (ja) | 2018-03-15 |
| JP2018506964A5 true JP2018506964A5 (https=) | 2019-05-23 |
| JP6850255B2 JP6850255B2 (ja) | 2021-03-31 |
Family
ID=56284963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535814A Expired - Fee Related JP6850255B2 (ja) | 2014-12-30 | 2015-12-28 | 抗−ｃｄ４７抗体及びその使用 |
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10870699B2 (https=) |
| EP (1) | EP3240569A4 (https=) |
| JP (2) | JP6850255B2 (https=) |
| KR (1) | KR102489471B1 (https=) |
| CN (1) | CN107530421B (https=) |
| AU (1) | AU2015374301B2 (https=) |
| BR (1) | BR112017014258A2 (https=) |
| CA (1) | CA2972604C (https=) |
| CL (1) | CL2017001736A1 (https=) |
| CO (1) | CO2017007673A2 (https=) |
| EA (1) | EA037654B1 (https=) |
| EC (1) | ECSP17041865A (https=) |
| HK (1) | HK1245154A1 (https=) |
| MX (1) | MX391051B (https=) |
| SG (2) | SG10202007176TA (https=) |
| WO (1) | WO2016109415A1 (https=) |
| ZA (1) | ZA201704467B (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| KR20170138574A (ko) * | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| CN109689684B (zh) * | 2016-07-06 | 2022-09-23 | 细胞基因公司 | 具有低免疫原性的抗体及其用途 |
| CN109790215B (zh) | 2016-09-29 | 2023-06-30 | 北京韩美药品有限公司 | 异源二聚体免疫球蛋白构建体和其制备方法 |
| BR112019008010A2 (pt) | 2016-10-20 | 2019-07-09 | I-Mab | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| US11352425B2 (en) * | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| JP7031810B2 (ja) | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 |
| EP3574009A4 (en) * | 2017-01-26 | 2020-11-25 | Zlip Holding Limited | CD47 ANTIGEN BINDING UNIT AND ITS USES |
| WO2018152033A1 (en) * | 2017-02-14 | 2018-08-23 | Promab Biotechnologies, Inc. | Cd47-car-t cells |
| BR112019020185A2 (pt) | 2017-03-27 | 2020-06-02 | Celgene Corporation | Métodos e composições para redução da imunogenicidade |
| MX2019012295A (es) | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
| JP7262440B2 (ja) * | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| EP3668897B1 (en) * | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| KR102366853B1 (ko) * | 2017-11-10 | 2022-02-23 | 아이-맵 바이오파마 유에스 리미티드 | Cd47 항체 및 사이토카인을 포함하는 융합 단백질 |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| WO2019109876A1 (zh) | 2017-12-04 | 2019-06-13 | 北京韩美药品有限公司 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| SG11202006877PA (en) * | 2018-01-24 | 2020-08-28 | Nanjing Legend Biotech Co Ltd | Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN112566662A (zh) | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| SG11202104301SA (en) * | 2018-10-31 | 2021-05-28 | I Mab Biopharma Us Ltd | Novel cd47 antibodies and methods of using same |
| WO2020177733A1 (zh) | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| TW202045550A (zh) | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
| CN114206912B (zh) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| CN112516301B (zh) * | 2019-09-17 | 2025-03-18 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体的液体制剂及其制备方法 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| JP7520972B2 (ja) * | 2019-10-25 | 2024-07-23 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗ｃｄ４７抗体及びその使用 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| BR112022017136A2 (pt) | 2020-02-28 | 2022-10-11 | Tallac Therapeutics Inc | Conjugação mediada por transglutaminase |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US20230220075A1 (en) | 2020-06-22 | 2023-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| JP7789304B2 (ja) * | 2020-07-31 | 2025-12-22 | バイオ－テラ ソリュ－ションズ，エルティーディー． | Ｃｄ４７抗体及びその応用 |
| CA3192331A1 (en) * | 2020-09-14 | 2022-03-17 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| JP2023545983A (ja) | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| WO2022135460A1 (zh) * | 2020-12-23 | 2022-06-30 | 广东菲鹏制药股份有限公司 | 一种靶向cd47的抗体及其应用 |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
| CN116635426A (zh) * | 2021-01-08 | 2023-08-22 | 北京韩美药品有限公司 | 特异性结合cd47的抗体及其抗原结合片段 |
| MX2023009717A (es) * | 2021-02-19 | 2024-01-08 | Shaperon Inc | Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo. |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024005423A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | 인간 FCγRS 결합력이 제거된 당화 FC 변이체들 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119866341A (zh) * | 2022-07-10 | 2025-04-22 | 爱莫布瑞斯疗法公司 | 重组抗体产生的无细胞方法 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120390653A (zh) | 2022-12-09 | 2025-07-29 | 辉瑞大药厂 | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179135A1 (en) * | 2024-02-23 | 2025-08-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using targeted pore-forming agents |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE60042789D1 (de) | 1999-11-29 | 2009-10-01 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| NZ578870A (en) | 2007-03-20 | 2012-01-12 | Lilly Co Eli | Anti-sclerostin antibodies |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| EP2477648B1 (en) | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| SI2804617T1 (sl) * | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| CN105101997B (zh) * | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| CA2909516C (en) * | 2013-04-19 | 2023-03-07 | Sutro Biopharma, Inc. | Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| BR112018005322A2 (pt) | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
-
2015
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en not_active Ceased
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh not_active Expired - Fee Related
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active Active
- 2015-12-28 HK HK18104961.7A patent/HK1245154A1/zh unknown
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 MX MX2017008819A patent/MX391051B/es unknown
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en not_active Ceased
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja not_active Expired - Fee Related
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt not_active IP Right Cessation
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en not_active Withdrawn
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506964A5 (https=) | ||
| US20260085115A1 (en) | Cd3 binding antibodies | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2021524256A5 (https=) | ||
| AU2017281034A1 (en) | CD3 binding antibodies | |
| JP2013515508A5 (https=) | ||
| JP2012526558A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2013519690A5 (https=) | ||
| IL301330A (en) | CD47-CD38 bispecific antibodies | |
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| JPWO2019223733A5 (https=) | ||
| EP4594358A1 (en) | Multispecific antibodies and methods of use thereof | |
| WO2014072741A1 (en) | Humanised antibody and method of production thereof | |
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| AU2024362545A1 (en) | Sirp antibodies for treatment of hemophagocytic lymphohistiocytosis | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| JPWO2019141732A5 (https=) | ||
| AU2024365034A1 (en) | Sirp antibodies for treatment of cancer | |
| JPWO2021052349A5 (https=) | ||
| CN116462764A (zh) | 靶向cd47和her2的多特异性抗体及其用途 | |
| WO2025226685A1 (en) | Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections | |
| US20240141062A1 (en) | Cd47-cd38 bispecific antibodies | |
| TW202608477A (zh) | 用於治療愛潑斯坦—巴爾病毒感染之ＳＩＲＰα、β、γ抗體 | |
| JP2021519589A5 (https=) |